🔍HER2 PARADIGM Trial now enrolling 🔹HER2-0 and HER2-0+ pts with MBC 🔹s/p 1 line of therapy ➡️T-DXd until progression 🎯 HER2 & TROP2 Quantitative immunofluorescence on biopsy sample NCT06750484 Love working with this outstanding Yale Breast & @yalepathology.bsky.social team! @yalecancer.bsky.social

🚨Wisdom Trial🚨 🔹randomized women to risk based bca screening vs annual screening 📍risk based: 9 genes, PRS, BCSC v2 model➡️ 4 risk groups guided frequency of screening ✅ rate of stage IIB ca noninferior to annual screening 🔹rate of breast biopsies was not lower #SABCS25

📣lidERA trial📣 🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years 🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014 🔸Arthralgias similar 📍1st trial to report benefit of SERD in the adjuvant tx 📋Looking forward to further data & other trials including CDK4/6i & SERDs💊 #SABCS25

🚨HER2CLIMB05 🚨 🔹Pts HER2+ MBC s/p THP x 4-8 cycles ➡️ HP + tucatinib vs HP 🔹PFS 24.9m vs 16.3m p<.0001 🔹HR- 24.9m vs 12.6m 🔹HR+ 25m vs 18m ⚠️ Increase in diarrhea and hepatic AEs 🔹Control arm had inferior PFS when compared to DB-09 control arm #SABCS25 #bcsm

Powerful message from Dr. Amy Beumer at #SABCS25: It’s time to “fix the toxic friendship” and design dosing with patients—balancing side effects, quality of life, and longevity. @maryamlustberg.bsky.social @sabcs.bsky.social

📌Starting #SABCS25 off with a discussion of the Advanced Breast Cancer (ABC) Global Decade Report 📈 🔸improved 5 year OS 26% ➡️33% 🔸improvement in QOL, but 79% report negative QOL 🔸access to care gaps have widened ✅ 10 goals 2025-2035 #bcsm @maryamlustberg.bsky.social

💡Phenomenal @onclive.bsky.social Fellows Forum ahead of #SABCS25 presenting important research, learning about advancing our careers, and making connections with the future leaders in breast oncology 🤝 thankful for the [email protected] @brianato.bsky.social

📍Thought provoking end to the Lynn Sage Breast Cancer Symposium discussing the goals of de-escalation in low risk, escalation in high risk, and individualized treatment in intermediate risk patients. Thankful for the opportunity to attend!✨#LSBC25 @luriecancer.bsky.social

💡Fabulous first day of the Lynn Sage Breast Cancer Symposium discussing obesity, sustainability, breast reconstruction, pathology, AI in oncology, approaches to management cans so much more ✨Thank you Lynn Sage for the travel award!💐 #LSBC25 @luriecancer.bsky.social

Excited to have joined Dr. Winer and Etienne to discuss medical oncology training, the future of oncology, and more! 🎙️🩺 @yalecancer.bsky.social

Yale Heme/Onc fellows riding for our patients, families, and cancer research 🧬 at the 15th annual Closer to Free Ride! 🚴🏼‍♀️💨 @ctfride.bsky.social @yalecancer.bsky.social

On September 6, 2025, I’ll be participating in the Closer to Free Ride to to raise funds to support cancer research and care for those who need it most - the patients, the families, and our team @yalecancer.bsky.social and Smilow Cancer Hospital Please consider donating to my ride!🚴🏻‍♀️

Amazing talk #ASCO2025 Highlights in MBC @maryamlustberg.bsky.social @yalecancer.bsky.social 📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations

We have great representation in this morning's #ASCO25 poster session in Hall A! Stop by and support our presenters: Drs. Soki Kashima, Tara Sanft, Zachary Yochum, Ro Malik, @braunmdphd.bsky.social, Aarti Bhatia, @ncasasanta.bsky.social, Jing Du, and Ismail Ajjawi. @yaleschoolofmed.bsky.social

🚨Practice changing interim results DESTINY-Breast09 evaluating 1st Line T-DXd + P vs THP in HER2+ MBC 🔹PFS 40.7 m vs 26.9 m! 🔹PFS2 not reached vs 36.5 m 🔹 OS immature #ASCO2025

Lots of buzz around TBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰ ➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬 🔸54% ctDNA <100 ppm after NAT 🔸NPV for residual disease 60%

Innovative SERENA-6 trial: at molecular progression switch to SERD w/ continuation of CDK4/6i in HR+ MBC improved PFS1✅ 🔹PFS2 & OS not mature 🔹 Improved TTD in QOL 🔹Control group PFS still 9.2 m 🔹Awaiting data on clearance of ctDNA after switch #ASCO2025

Inspirational words on positioning yourself for success by these four women physician leaders! Sharing advice with early career women in oncology. Now we have the tools for success🛠️✨#ASCO2025 @maryamlustberg.bsky.social @drgattimays.bsky.social @yalecancer.bsky.social

Outstanding talk by Dr. Ian Krop on antibody drug conjugates in the era of targeted therapies. 🔬So much groundbreaking work has been done and there’s still more work to do in understanding mechanism, mechanisms of resistance, and biomarkers for response📈📌 #ASCO2025

INAVO120 trial: In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. nej.md/3Zje7Vt #ASCO25 @ascocancer.bsky.social

In advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with ESR1 mutations but not in the full patient population. Full VERITAC-2 phase 3 trial results: nej.md/3ZoCL7g #ASCO25 @ascocancer.bsky.social

Impressive & practice changing ASCENT-04/KEYNOTE-D19 evaluating sacituzumab go ite an + pembro vs chemo + pembro in 1st Line PDL1+ metastatic TNBC demonstrating PFS 11.2 vs 7.8 months! 🚨Much needed improvement in 1st Line metastatic TNBC #ASCO2025

Congratulations to our faculty and fellows on their awards from @conquercancer.bsky.social at #ASCO25! (l-r) Drs. Mariya Rozenblit, @ncasasanta.bsky.social, Devora Isseroff and Benjamin Lu. Learn more ➡️ yalecancercenter.org/news-article... @ascocancer.bsky.social @yaleschoolofmed.bsky.social

Great start to #ASCO2025 with Yale Cancer Center and at the @conquercancer.bsky.social Awards Ceremony🏆 So grateful to have the opportunity to research improved biomarkers for ADC response in patients with HER2-low, HER2-ultralow, and HER2 0 breast cancer 🔬🩺

Looking forward to seeing the data for neoadjuvant T-DXd ➡️ THP in patients with high risk, locally advanced HER2+ breast cancer! 💉 Rates of ILD similar among T-DXd/THP vs ddAC-THP arms🫁

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC #BCSM #oncology www.onclive.com/view/sacituz...

T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer #BCSM #oncology www.onclive.com/view/t-dxd-p...